Fully funded by 
Content independently selected
Shows 25% reduction in risk for death in interim analysis.
Biopsy needed to select patients for salvage treatment.
AQUARIUS shows advantage in terms of fatigue and cognitive function.
Case-control study finds higher risk with meat intake.
But be cautious: longer follow-up is needed to assess the freedom from distant metastases at ten years
Largest trial ever on urothelial cancer sees higher response rates with the addition of atezolizumab.
Cabazitaxel superior to abiraterone, enzalutamide as a third-line treatment.
Targeted and immunotherapy for GI and GU tumours.
“Practice-changing” study is first success with targeted therapy in this setting.
The number of new therapies and biomarkers is rapidly increasing.
Study is the first to assess a tailored approach to boosting NIVO treatment with IPI.
Strategies to better tailor effective treatments are needed.
Meta-analysis combines evidence from three trials.
Slightly higher risk for upstaging observed.
Study suggests early prostate cancer screening and long-term monitoring should be considered for these men.
IMPACT study points to need for regular PSA screenings.
Bisphosphonates, denosumab are preferred.
